Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102115 · ClinicalTrials.gov registry record · Phase 1
Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
A Phase 1 study, sponsored by Light Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00102115 is a Phase 1 study that was terminated before completion, run by Light Sciences. The registered enrollment target is 27 participants.
The verdict
NCT00102115, a Phase 1 study, was terminated before completion, sponsored by Light Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
Interventions
- DRUG Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102115
The ClinicalTrials.gov registry entry for NCT00102115 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Light Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talaporfin Sodium (LS11) Photodynamic Therapy (PDT) is the first listed.
NCT00102115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102115 about?
NCT00102115 is a clinical study titled "Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease". The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
What is the current status of trial NCT00102115?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2004-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00102115?
The interventions under investigation include: Talaporfin Sodium (LS11) Photodynamic Therapy (PDT) (DRUG).
Who is sponsoring clinical trial NCT00102115?
This trial is sponsored by Light Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.